Clinical Trial Update: Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial [Phase 2]

View source ↗

Summary

Phase II trial evaluating the combination of Pyrotinib Maleate, a CDK4/6 inhibitor, and letrozole for stage II-III triple-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CDK4/6 inhibitor
• Letrozole (letrozole)
• Pyrotinib maleate (pyrotinib)

Snippet

Sponsor: Shengjing Hospital | Conditions: Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING